Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    Open Studies | "Measles"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Measles" (17 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau
Condition: Measles
Interventions: Other: SMS reminder message;   Other: Voice call + SMS message
2 Recruiting Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Condition: Measles
Intervention: Biological: MMR vaccination
3 Not yet recruiting Mobile and Scalable Innovations for Measles Immunization: a Randomized Controlled Trial
Condition: Measles
Interventions: Behavioral: SMS reminder;   Behavioral: Unconditional Incentive
4 Recruiting Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine
Conditions: Encephalitis, Japanese;   Measles;   Mumps;   Rubella
Interventions: Biological: CD-JEV;   Biological: MMR
5 Not yet recruiting Trial of Measles Virotherapy in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
Condition: Recurrent Non-Small Cell Lung Cancer
Interventions: Biological: MV-NIS;   Biological: Nivolumab
6 Not yet recruiting Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Conditions: Medulloblastoma, Childhood, Recurrent;   Atypical Teratoid/Rhabdoid Tumor;   Medulloblastoma Recurrent
Interventions: Biological: Modified Measles Virus;   Biological: Modified Measles Virus Lumbar Puncture
7 Recruiting UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
Condition: Multiple Myeloma
Intervention: Drug: MV-NIS
8 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
9 Recruiting A Second Dose of Measles Vaccine (MV) in the Second Year of Life
Conditions: Child Mortality;   Child Morbidity
Intervention: Biological: Measles vaccine
10 Not yet recruiting Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Condition: Malaria Vaccines
Interventions: Dietary Supplement: Vitamin A;   Biological: Candidate Plasmodium falciparum malaria vaccine;   Biological: MR-Vac;   Biological: Stamaril
11 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Neoplasm
Interventions: Biological: Carcinoembryonic Antigen-Expressing Measles Virus;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
12 Recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Pharmacological Study
13 Recruiting MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Conditions: Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Clear Cell Tumor;   Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Serous Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Topotecan Hydrochloride
14 Recruiting Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Peripheral Nerve Sheath Tumor;   Neurofibromatosis Type 1;   Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions: Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Quality-of-Life Assessment;   Procedure: Single Photon Emission Computed Tomography
15 Recruiting Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant
Conditions: RENAL INSUFFICIENCY, CHRONIC;   LIVER FAILURE, ACUTE;   HEART DISEASE
Intervention: Biological: ProQuad
16 Recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
Conditions: Malignant Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Procedure: Mesenchymal Stem Cell Transplantation;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
17 Recruiting Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   HER2/Neu Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Head and Neck Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Study has passed its completion date and status has not been verified in more than two years.